Clinical Trial Update: Association of FcγRIIIA Polymorphism and THPO Expression With Response to Eltrombopag in Refractory ITP Patients [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial investigates how FcγRIIIA polymorphism and THPO expression relate to response to eltrombopag in patients with refractory immune thrombo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Eltrombopag (eltrombopag)

Snippet

Sponsor: National Institute of Blood and Marrow Transplant (NIBMT), Pakistan | Conditions: Immune Thrombocytopenic Purpura (ITP) | Phase 3 | Status: UNKNOWN